Investors have been anxiously awaiting the results by Marker Therapeutics of their phase 1/2 trial known as TACTOPS, which investigates the use of Multi TAA technology in the treatment of pancreatic cancer. Although Marker has demonstrated the scope and breadth of their technology in liquid cancers, investors were eager to see whether the platform could be extended to the treatment of solid cancers.
For those who don't know, Multi TAA therapy is an innovative platform whereby they take the patients own T-cells through a standard blood draw , expand them without genetic modification, and train